Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

John Calhoun

Internal Medicine Charleston, SC Medical Doctor

NPI 1770845141 CMS profile 983463

169 Ashley Ave, Room 202 Main Hospital Msc333, Charleston, SC 29425

Open in the dashboard

General payments

$2,995

226 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, John Calhoun of Charleston, SC is reported in the CMS Open Payments database as having received $2,995 across 226 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 84th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $360 14
2024 General $206 12
2023 General $282 14
2022 General $581 47
2021 General $629 56
2020 General $426 31
2019 General $512 52

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • John Calhoun
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to John Calhoun were reported at $360. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year John Calhoun Internal Medicine median Middle half National median
2019 $512 $159 $48–$570 $163
2020 $426 $119 $33–$402 $114
2021 $629 $135 $37–$521 $132
2022 $581 $141 $42–$496 $149
2023 $282 $149 $45–$519 $160
2024 $206 $154 $47–$537 $164
2025 $360 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Janssen Pharmaceuticals, Inc $583 67 payments
  2. AbbVie, Inc. $459 30 payments
  3. Novo Nordisk Inc $300 34 payments
  4. GlaxoSmithKline, LLC. $215 12 payments
  5. Nevro Corp. $197 9 payments
  6. Amarin Pharma Inc. $149 8 payments
  7. Novartis Pharmaceuticals Corporation $115 8 payments
  8. Abiomed $115 2 payments
  9. Abbott Laboratories $110 8 payments
  10. AstraZeneca Pharmaceuticals LP $97 7 payments
  11. Other $655 41 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $2,984 225 payments
  2. Education $12 1 payment
Products named General payments · program years 2019–2025
  1. XARELTO $553 65 payments
  2. Ozempic $272 32 payments
  3. RYBELSUS $252 31 payments
  4. QULIPTA $227 14 payments
  5. INVOKANA $220 34 payments
  6. TRELEGY ELLIPTA $215 12 payments
  7. Omnia $152 7 payments
  8. VRAYLAR $139 8 payments
  9. ENTRESTO $115 8 payments
  10. FreeStyle Libre 2 $91 7 payments
  11. Other $1,363 94 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 207 drugs

Part D claims

15,668

Median for Internal Medicine: 777

Drug cost

$1,332,407

Median for Internal Medicine: $73,373

Branded share of claims

21.8%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Mounjaro Tirzepatide Brand 224 $245,310
Eliquis Apixaban Brand 176 $157,684
Januvia Sitagliptin Phosphate Brand 89 $106,072
Ozempic Semaglutide Brand 84 $94,911
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 96 $78,500
Jardiance Empagliflozin Brand 57 $78,239
Xarelto Rivaroxaban Brand 51 $40,408
Tresiba Flextouch U-200 Insulin Degludec Brand 27 $31,398
Nuedexta Dextromethorphan Hbr/Quinidine Brand 20 $30,819
Breo Ellipta Fluticasone/Vilanterol Brand 63 $28,134

The 10 drugs with the highest cost, of 207 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 92 billing codes

Paid by Medicare

$229,668

Of which drugs: $5,788

Medicare patients

707

Average age 76

Services billed

7,259

388 women, 319 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 57%
Diabetes 40%
Ischemic heart disease 37%
Chronic kidney disease 33%
Depression 30%
Heart failure 29%
Atrial fibrillation 29%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90662 Office 62 62 $4,557
Influenza vaccine, trivalent derived from cell cultures 90661 Office 23 23 $794
Injection, methylprednisolone acetate, 1 mg J1010 Office 30 1,163 $113
Injection, ketorolac tromethamine, per 15 mg J1885 Office 18 88 $45
Injection, methylprednisolone acetate, 40 mg J1030 Office 16 17 $40
Injection, ceftriaxone sodium, per 250 mg J0696 Office 23 97 $33
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 46 204 $15

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

3 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
TRELEGY ELLIPTA
  • GlaxoSmithKline, LLC. $91
$91 96 —
QULIPTA
  • AbbVie, Inc. $73
$73 — —
Repatha
  • Amgen Inc. $14
$14 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

226 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in South Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record